Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Kennedy

Showing results (991-1000 of 1,021) with videos related to

Pageof 103
Sort By:
Cancer Cell|March 16, 2005
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigenCharles G Drake, Amy D H Doody, Marianne A Mihalyo, et al.
Circulation|August 19, 2007
Tyrosine hydroxylase, the rate-limiting enzyme in catecholamine biosynthesis: discovery of common human genetic variants governing transcription, autonomic activity, and blood pressure in vivoFangwen Rao, Lian Zhang, Jennifer Wessel, et al.
Annals of the New York Academy of Sciences|January 6, 2009
Adrenergic polymorphism and the human stress responseFangwen Rao, Lian Zhang, Jennifer Wessel, et al.
Cancer Biology & Therapy|September 13, 2013
The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicityJianMin Lin, Jared L Spidel, Christopher J Maddage, et al.
Circulation|April 18, 2007
Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertensionFangwen Rao, Gen Wen, Jiaur R Gayen, et al.
Clinical Radiology|January 20, 2026
IO1-UK: a cross-sectional study to re-evaluate the provision of interventional oncology services across the United KingdomD Velazquez-Pimentel, J Pancholi, P Jenkins, et al.
Brain and Cognition|December 21, 2023
Validation of the cognitive section of the Penn computerized adaptive test for neurocognitive and clinical psychopathology assessment (CAT-CCNB)Akira Di Sandro, Tyler M Moore, Eirini Zoupou, et al.
Bioorganic & Medicinal Chemistry Letters|March 30, 2001
Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubilityA Guzman-Perez, R T Wester, M C Allen, et al.
Journal for Immunotherapy of Cancer|June 12, 2021
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanomaYousef Zakharia, Robert R McWilliams, Olivier Rixe, et al.
Mayo Clinic Proceedings|July 25, 2000
Prospective evaluation of Roux-en-Y gastric bypass as primary operation for medically complicated obesityB M Balsiger, F P Kennedy, H S Abu-Lebdeh, et al.
Pageof 103

Showing results (991-1000 of 1,021) with videos related to

Sort By:
Pageof 103
Cancer Cell|March 16, 2005
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigenCharles G Drake, Amy D H Doody, Marianne A Mihalyo, et al.
Circulation|August 19, 2007
Tyrosine hydroxylase, the rate-limiting enzyme in catecholamine biosynthesis: discovery of common human genetic variants governing transcription, autonomic activity, and blood pressure in vivoFangwen Rao, Lian Zhang, Jennifer Wessel, et al.
Annals of the New York Academy of Sciences|January 6, 2009
Adrenergic polymorphism and the human stress responseFangwen Rao, Lian Zhang, Jennifer Wessel, et al.
Cancer Biology & Therapy|September 13, 2013
The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicityJianMin Lin, Jared L Spidel, Christopher J Maddage, et al.
Circulation|April 18, 2007
Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertensionFangwen Rao, Gen Wen, Jiaur R Gayen, et al.
Clinical Radiology|January 20, 2026
IO1-UK: a cross-sectional study to re-evaluate the provision of interventional oncology services across the United KingdomD Velazquez-Pimentel, J Pancholi, P Jenkins, et al.
Brain and Cognition|December 21, 2023
Validation of the cognitive section of the Penn computerized adaptive test for neurocognitive and clinical psychopathology assessment (CAT-CCNB)Akira Di Sandro, Tyler M Moore, Eirini Zoupou, et al.
Bioorganic & Medicinal Chemistry Letters|March 30, 2001
Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubilityA Guzman-Perez, R T Wester, M C Allen, et al.
Journal for Immunotherapy of Cancer|June 12, 2021
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanomaYousef Zakharia, Robert R McWilliams, Olivier Rixe, et al.
Mayo Clinic Proceedings|July 25, 2000
Prospective evaluation of Roux-en-Y gastric bypass as primary operation for medically complicated obesityB M Balsiger, F P Kennedy, H S Abu-Lebdeh, et al.
Pageof 103